This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aveo, Delcath FDA Panel Live Blog

BOSTON ( TheStreet) -- Welcome to the doubleheader FDA advisory panel live blog: The morning panel features Aveo Oncology (AVEO - Get Report) and its kidney cancer drug tivozanib. In the afternoon session, Delcath Systems (DCTH - Get Report) brings the Melblez liver-tumor therapy in front of the FDA's outside experts.

The panel experts will consider the efficacy and safety of tivozanib and Melblez and vote to recommend approval -- or not. The final approval decision rests with the FDA.

Expect trading in both Aveo and Delcath to be halted during their respective panel sessions. Both stocks have been under pressure this week on FDA reviews which raised concerns and questions about the clinical benefit and/or safety of tivozanib and Melblez. It will be the job of Aveo and Delcath to counter these concerns and convince the panel members that their respective products deserve FDA approval.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AVEO $1.89 -1.60%
DCTH $1.04 0.00%
AAPL $132.78 1.90%
FB $82.59 1.30%
GOOG $556.69 -1.50%

Markets

DOW 18,132.96 +52.82 0.29%
S&P 500 2,120.86 +3.17 0.15%
NASDAQ 5,101.3720 +9.2870 0.18%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs